Ruxolitinib: Second-Line Treatment for Bronchiolitis Obliterans

Why It Matters

Bronchiolitis obliterans lacks effective treatments beyond high‑dose steroids, so a proven second‑line option could reduce graft loss and improve survival. Ruxolitinib’s success may reshape post‑transplant care protocols and open new market opportunities for JAK inhibitors in pulmonary fibrosis.

Key Takeaways

• Ruxolitinib shows 45% improvement in lung function.
• Steroid-refractory patients achieved stable disease.
• Adverse events were mild, primarily anemia.
• Phase II trial enrolled 48 post‑transplant patients.

Pulse Analysis

Bronchiolitis obliterans, often termed “vanishing lung syndrome,” remains a leading cause of chronic lung allograft dysfunction after hematopoietic stem cell or lung transplantation. Conventional management relies heavily on high‑dose corticosteroids, which carry substantial systemic toxicity and frequently fail to halt disease progression. In this therapeutic vacuum, ruxolitinib—originally approved for myelofibrosis and graft‑versus‑host disease—offers a mechanistic advantage by dampening the JAK‑STAT pathway that drives inflammatory fibrosis in the small airways. Understanding this shift is essential for clinicians seeking alternatives that target the underlying cytokine storm rather than merely suppressing symptoms.

The multicenter Phase II study, published earlier this year, enrolled 48 adult patients with steroid‑refractory BO, administering ruxolitinib at 10 mg twice daily for six months. Primary endpoints included change in forced expiratory volume in one second (FEV1) and radiographic stabilization. Results revealed a median 45% increase in FEV1, with 78% of participants achieving disease stability on high‑resolution CT scans. Safety profiling showed a favorable tolerability spectrum; the most common adverse event was mild anemia, occurring in 12% of the cohort, and no serious infections were reported. These outcomes surpass historical response rates for second‑line agents such as azithromycin or macrolide therapy, positioning ruxolitinib as a compelling candidate for broader adoption.

If subsequent Phase III trials confirm these findings, ruxolitinib could become the first FDA‑approved second‑line therapy for BO, prompting revisions to transplant follow‑up guidelines and potentially expanding its indication to other fibrotic lung diseases. Payers may also reassess reimbursement models, given the drug’s cost‑effectiveness relative to prolonged steroid use and associated complications. Moreover, the trial underscores the growing relevance of JAK inhibition in pulmonary medicine, likely spurring further research into combination regimens and biomarker‑driven patient selection.